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ARTICLE
Tissue-resident macrophages in omentum promote
metastatic spread of ovarian cancer
Anders Etzerodt1,2, Morgane Moulin1,3, Thomas Koed Doktor4, Marcello Delfini1, Noushine Mossadegh-Keller1, Marc Bajenoff1, Michael H. Sieweke1,5,
Søren Kragh Moestrup2,6, Nathalie Auphan-Anezin1, and Toby Lawrence1,3,7
Experimental and clinical evidence suggests that tumor-associated macrophages (TAMs) play important roles in cancer
progression. Here, we have characterized the ontogeny and function of TAM subsets in a mouse model of metastatic ovarian
cancer that is representative for visceral peritoneal metastasis. We show that the omentum is a critical premetastatic niche
for development of invasive disease in this model and define a unique subset of CD163+ Tim4+ resident omental macrophages
responsible for metastatic spread of ovarian cancer cells. Transcriptomic analysis showed that resident CD163+ Tim4+ omental
macrophages were phenotypically distinct and maintained their resident identity during tumor growth. Selective depletion
of CD163+ Tim4+ macrophages in omentum using genetic and pharmacological tools prevented tumor progression and
metastatic spread of disease. These studies describe a specific role for tissue-resident macrophages in the invasive progression
of metastatic ovarian cancer. The molecular pathways of cross-talk between tissue-resident macrophages and disseminated
cancer cells may represent new targets to prevent metastasis and disease recurrence.
Introduction
Macrophages populate all human tissues, and their involvement
in tumor progression and metastasis is well documented (Noy
and Pollard, 2014). Recent advances in our understanding of
macrophage biology suggest that tissue-resident macrophages
and infiltrating tumor-associatedmacrophages (TAMs) display a
high degree of heterogenity, in terms of both phenotype and
ontogeny. However, our understanding of the physiological
relevance of this heterogeneity and its implications for tumor
development is still limited. In particular, the role of resident
macrophages in tissue-specific tumor initiation and progression
is unclear.
Ovarian cancer is the eighth leading cause of cancer-related
death in women worldwide and has a particularly poor prog-
nosis due to almost 80% of cases being diagnosed with late-stage
invasive disease (Ferlay et al., 2018). In particular, high-grade
serous ovarian carcinoma (HGSOC), the most frequent and ag-
gressive form of ovarian cancer, is characterized by the forma-
tion of malignant ascites and peritoneal metastases, which
results in a disastrous prognosis (Lengyel, 2010). HGSOC origi-
nates from transformation of fallopian tube or ovarian surface
epithelial cells that disseminate at early stages into the
peritoneal cavity by exfoliation (Lengyel, 2010). Due to the lack
of any anatomical barriers, exfoliated cancer cells are carried by
the peritoneal fluid and spread throughout the abdominal cavity
in a process termed transcolemic metastasis (Kipps et al., 2013).
Several reports have also suggested that ovarian cancer cells in
ascites acquire cancer stem cell (CSC)–like properties that may
play an important role in metastatic spread, chemosensitivity,
and disease recurrence after therapy (Bapat et al., 2005). The
most frequent site for metastasis in HGSOC is the omentum
(Sehouli et al., 2009), an apron of visceral adipose tissue in the
abdomen formed from a fold of the peritoneal mesothelium.
Omentum contains a high density of lymphoid aggregates
known as milky spots or fat-associated lymphoid clusters
(FALCs), which are thought to contribute to peritoneal and in-
testinal immunity (Krist et al., 1995; Rangel-Moreno et al., 2009;
Bénézech et al., 2015). The tropism of ovarian cancer cells for the
omentum and its implications for disease progression are not yet
fully understood. Several reports have suggested that FALCs
play an active role in colonization of omentum (Hagiwara et al.,
1993), but the tumor-promoting function of FALCs was shown to
be independent of both B and T lymphocytes (Clark et al., 2013).
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Myeloid cells are also abundant in FALCs, and macrophage
density was recently shown to increase proportionally with
disease score in omenta from ovarian cancer patients (Pearce
et al., 2018). However, the specific role of omental macrophages
in colonization and disease progression remains to be explored.
Tissue-resident macrophages perform trophic functions that
contribute to organ development, tissue remodeling, and ho-
meostasis (Pollard, 2009). Experimental evidence has shown
that TAMs contribute to tumor progression by promoting an-
giogenesis, matrix remodeling, and epithelial-to-mesenchymal
transition (EMT; Raggi et al., 2016), which ultimately leads to
increased cell invasion and metastasis (Noy and Pollard, 2014).
These properties reflect the trophic functions of macrophages
in development, and consistent with these developmental
functions, the transcriptome of TAMs from mammary gland
tumors has been shown to be enriched for genes that also define
embryonic macrophages (Ojalvo et al., 2010). Until recently, it
was thought that tissue macrophages were maintained from
bone marrow–derived monocyte precursors, with the exception
of the brain microglia and Langerhans cells in the skin (Ginhoux
et al., 2010; Ginhoux and Merad, 2010), and the same has gen-
erally been assumed for TAMs (Lahmar et al., 2016). However,
recent advances in molecular techniques that allow the fate-
mapping of macrophages in vivo have revealed that most tis-
sue macrophages originate from embryonic precursors and can
be maintained by local proliferation with little input from the
bone marrow (Schulz et al., 2012). Subsequent studies have
shown that tissue-resident macrophages of embryonic origin
Figure 1. Omentum is a critical premetastatic niche for ovarian cancer cells. (A) Location of the omentum in the abdominal cavity of mice. (B) In vivo
bioluminescence imaging of mice at 1, 21, 35, and 63 d after i.p. injection of 106 ID8-Luc cells; scale bar: 1 cm. (C) H&E stain of frozen omental sections from
naive mice or 35 and 63 d after injection of ID8-Luc cells; scale bar: 100 µm. (D) Ex vivo luminescence analysis of omentum and ascites. RLU, relative lu-
minescent unit. Data are represented as mean ± SEM of n = 5, and statistically significant difference was calculated using two-way ANOVA followed by Tukey
post hoc test; ***, P < 0.001. (E) Tumor nodules on the diaphragm of mice 10 wk after injection of ID8-Luc cells. (F) In vivo bioluminescence analysis of
omentectomized, sham-operated, or control (Ctrl) mice from 0–63 d after injection of ID8-Luc cells. cps, counts per second. Data are represented as mean ±
SEM of n = 5, and statistically significant difference was calculated using two-way ANOVA followed by Tukey post hoc test; **, P < 0.01. (G) End-point analysis
of malignant ascites in omentectomized or control mice 63 d after injection of ID8-Luc cells. Data are represented as mean ± SEM of n = 5, and statistically
significant difference was calculated using Kruskal-Wallis one-way ANOVA followed by Dunn’s multiple comparisons test; *, P < 0.05. All data are repre-
sentative of two independent experiments.
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can be gradually replaced by monocyte-derived cells to varying
degrees depending on the specific tissue (Ginhoux and
Guilliams, 2016). The functional implications of these distinct
developmental origins and their respective contributions to tu-
morigenesis have not yet been fully explored. However, recent
reports suggest that embryo-derived tissue-resident macro-
phages can proliferate during tumor development and have
distinct functions in tumor progression compared with
monocyte-derived TAMs (Zhu et al., 2017; Loyher et al., 2018).
It is therefore critically important to further understand the
specific axes of cross-talk between tissue-resident macrophages
and cancer cells, during both tumor initiation and the malignant
progression of disseminated tumor cells, as this may reveal new
targets to combat tumor progression and thwart the develop-
ment of invasive disease.
Here, we demonstrate that omentum represents a critical
premetastatic niche in a mouse model of metastatic ovarian
cancer and define a specific subset of tissue-resident macro-
phages in omentum that express CD163 and Tim4 and are re-
quired for the metastatic spread of ovarian cancer cells. Using
genetic fate-mapping and shielded chimera experiments, we
show that CD163+ Tim4+ omental macrophages are derived from
embryonic progenitors and maintained independently of bone
marrow–derived monocytes. Specific depletion of CD163+ Tim4+
macrophages, using genetic tools or antibody-targeted cytotoxic
liposomes, was sufficient to prevent the development of
metastatic disease, whereas depletion of monocyte-derived
TAMs had no impact. These studies suggest that specific inter-
actions between disseminated tumor cells and tissue-resident
CD163+ Tim4+ macrophages in the omentum promote the ma-
lignant progression of ovarian cancer. The molecular pathways
that underly these interactions may represent new therapeutic
targets for treatment of invasive metastatic disease.
Results
The omentum is a critical premetastatic niche for ovarian
cancer cells
The omentum is an adipose tissue formed from a fold of the
peritoneal mesothelium. In humans, the greater omentum cov-
ers the majority of the abdomen, whereas in mouse the omen-
tum is only a thin stretch of adipose tissue located between the
stomach, pancreas, and spleen (Fig. 1 A). The peritoneal spread
of ovarian cancer has been modeled in mice using the immor-
talized mouse ovarian epithelial cell line ID8 (Roby et al., 2000).
The i.p. injection of ID8 cells leads to the development of diffuse
peritoneal carcinomatosis and malignant ascites with a long la-
tency period (up to 12 wk), which has been widely used as a
model of late-stage ovarian cancer (Charles et al., 2009; Motz
et al., 2014; Lee et al., 2019). We used an ID8 cell line transduced
to express firefly luciferase (ID8-luc; Hagemann et al., 2008) to
monitor tumor progression after i.p. injection by noninvasive
Figure 2. Single-cell transcriptional profiling of omental macrophages after tumor colonization. (A) Whole-mount confocal imaging of omentum
showing the location of FALCs by visualizing collagen IV (ColIV, green), adipocytes (LipidTox, red), and leukocyte clusters (CD45, white); scale bar: 0.5 mm.
(B) Whole-mount imaging of ID8-Luc infiltration in the omentum 24 h after injection of ID8 cells. Pecam-1 staining for blood vessels (red), CD163 for mac-
rophages (green), CD45 for FALCs (white), and Qdot705 for ID8 cells (magenta); scale bar: 100 µm and 50 µm in magnification. (C) Two-dimensional rep-
resentation and clustering of single-cell TAM transcriptomes using UMAP (n = 16,514). (D) Heatmap showing the top 10 DEGs in each UMAP cluster. (E) Violin
plots showing expression of commonly used macrophage markers.
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bioluminescent imaging. We observed that ID8 cells localized
primarily to the omentum for up to 35 d before spreading
throughout the peritoneal cavity (Fig. 1 B). Infiltration of tumor
cells into the omentum was confirmed by histological analysis,
where visible tumor nodules could be observed within the adi-
pose tissue from 35 d (Fig. 1 C). From day 63, the entire omentum
was invaded by tumor cells, and only residual adipose tissue
remained (Fig. 1 C). Interestingly, despite the presence of obvi-
ous tumor nodules in omentum from day 35, accumulation of
ascitic ID8 cells was not detectable until >50 d after i.p. injection
(Fig. 1 D). Ultimately, ascites formation was associated with the
development of multiple distant metastases in the diaphragm
and peritoneal wall (Fig. 1 E), reflecting late-stage disease in
HGSOC patients. To establish the contribution of the omentum
to the disease course in this model, we transplanted ID8-luc cells
into omentectomized mice and monitored tumor growth.
Whereas sham-operated and control mice showed a comparable
course of tumor progression with accumulation of ascitic tumor
cells after 63 d, we observed only minimal tumor growth in
omentectomized mice, and ascitic cells were barely detectable
(Fig. 1, F and G). These data suggested that the omentum was a
critical premetastatic niche for tumor progression in this model
and not merely a receptive site for peritoneal metastasis.
Ovarian cancer cells colonize FALCs in close contact with
omental macrophages
The omentum has a particularly high density of FALCs, which
are thought to be important structures for capturing peritoneal
antigens (Rangel-Moreno et al., 2009; Fig. 2 A). Previous studies
have proposed that FALCs promote the colonization of omentum
by ovarian cancer cells; however, neither B or T lymphocytes
were shown to contribute to tumor growth (Clark et al., 2013).
To visualize the localization of ID8 cells in the omentum, we
labeled the cells with Qdots (Qtracker705) before i.p. injection
and analyzed omentum by whole-mount confocal imaging. 1 d
after injection, we observed that ID8 cells were located in the
vicinity of FALCs, an area densely populated by omental mac-
rophages (Fig. 2 B). To further characterize omental macrophages
after colonization with ID8 cells, we performed single-cell RNA
sequencing (scRNAseq) on macrophages isolated from omen-
tum 10 wk after injection of ID8 cells. Macrophages were
isolated by flow-assisted cell sorting with gating on CD11b+ F4/
80+ CD64+ cells and processed for scRNAseq analysis using the
10× Genomics Chromium platform. After filtering to exclude
doublets and dead cells, we obtained 16,392 single-cell tran-
scriptomes from four animals for downstream analysis. Uni-
form Manifold Approximation and Projection (UMAP)
clustering analysis identified 10 major cell clusters (Fig. 2 C).
Further analysis of the most significant differentially expressed
genes (DEGs) in each cluster identified several common mac-
rophage markers that were differentially expressed among
these subsets. We identified a single cluster coexpressing Lyve-1,
Cd163, and Tim4 (Fig. 2, D and E), which have previously been
used to characterize resident macrophages in various tissues.
Tim4 has been shown to be expressed by large peritoneal
macrophages (Rosas et al., 2014), T cell zone macrophages in
lymph nodes (Baratin et al., 2017), liver Kupffer cells (Scott
et al., 2016), and resident intestinal macrophages (De
Schepper et al., 2018). Lyve-1 was shown to be expressed by
perivascular macrophages (Lim et al., 2018) and more recently
by a subset of monocyte-derived interstitial macrophages
in various tissues (Chakarov et al., 2019). Finally, CD163 is
expressed by a number of tissue-resident macrophage pop-
ulations, including Kupffer cells, red pulp macrophages in
the spleen, and bone marrow macrophages (Etzerodt and
Moestrup, 2013). In addition to these three markers, several
additional cell surface markers have been used to characterize
tissue-resident macrophages. This includes CD169 (Siglec-1)
expression on bone marrow macrophages, alveolar macro-
phages, metallophilic macrophages in the spleen, and subcap-
sular sinus macrophages in the lymph nodes (Gray and Cyster,
2012). To further characterize the heterogeneity of omental
macrophages, we analyzed the expression of these markers by
flow cytometry. Gating on the CD11b+ myeloid cell fraction
(CD45.2+ Lin− [CD5, CD19, NK1.1, Ly6G, SiglecF]), we identified
macrophages as F4/80+ CD64+ cells (Fig. 3 A, i), whereas
monocytes were F4/80− CD64− CCR2+ (Fig. 3 A, ii). We observed
a gradient of CD169 expression, where only CD169hi cells
coexpressed Lyve-1 (Fig. 3 A, iii). Further analysis showed that
CD169− Lyve-1− and CD169int Lyve-1− cells were also negative for
CD163 and Tim4 expression (Fig. S1 B), indicating a less mature
phenotype. In contrast, CD169hi Lyve-1+ cells could be separated
into four distinct populations based on CD163 and Tim4 ex-
pression: CD163+ Tim4+ (P1), CD163+ Tim4− (P2), CD163− Tim4−
(P3), and CD163− Tim4+ (P4; Fig. 3 A, iv). This analysis cor-
roborated the UMAP clustering analysis on omental TAMs,
where P1 macrophages represent cluster 8, and P2macrophages
represent cluster 0 (Fig. 2, C–E). In contrast, Lyve-1+ P3 and
Lyve-1+ Tim4+ P4macrophages were not separated based on the
UMAP analysis.
We next analyzed the localization of these macrophage sub-
sets in omentum by whole-mount confocal imaging. We found
that CD169+ cells were distributed evenly throughout the tissue,
whereas CD169+ CD163+ cells were located at the interface be-
tween FALCs and the surrounding adipose tissue (Fig. 3 B).
Tim4+ CD163− cells were mainly located within FALCs, whereas
CD163+ Tim4+ cells were found only at the interface between
FALCs and the surrounding adipose tissue (Fig. 3 C), similarly to
CD169+ CD163+ cells (Fig. 3 B). Therefore, P1 (CD163+ Tim4+) and
P2 (CD163+ Tim4−) macrophages are specifically located in the
tissue surrounding FALCs, whereas P3 (CD163− Tim4−) macro-
phages are widely distributed throughout the adipose tissue, and
P4 (CD163− Tim4+) macrophages appear to be located within
FALCs.
To determine the dynamics of these macrophage subsets
during colonization of omentum by ovarian cancer cells and
tumor progression, we performed a kinetic analysis by flow
cytometry after transplantation of ID8 cells. Among the CD11b+
myeloid fraction, CCR2+ monocytes represent the most abun-
dant population in naive omentum, which remained unchanged
for up to 4 wk after ID8 cell injection (Fig. 3 D). After 4 wk, the
proportion of monocytes decreased coincidently with an in-
crease in CD169lo Lyve-1− macrophages, followed by a propor-
tional increase in both CD169lo Lyve-1− and CD169int Lyve-1− and
Etzerodt et al. Journal of Experimental Medicine 4 of 22
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CD169hi Lyve-1+ cells at 6 and 8 wk of tumor growth (Fig. 3 D).
The proportional increase in CD169hi Lyve-1+ macrophages ap-
peared to be driven by an increase in P3 (CD163− Tim4−). In
contrast, the proportion of P1 (CD163+ Tim4+), and to a lesser
extent P2 (CD163+ Tim4−), was significantly decreased compared
with normal omentum, whereas P4 (CD163− Tim4+) remained
relatively unchanged (Fig. 3 E).
In summary, these studies showed that ID8 cells colonize
the omentum in the vicinity of FALCs and juxtaposed to
resident CD163+ Tim4+ macrophages. As tumors progressed,
there was an increase in the proportion of CD169+ Lyve-1+
macrophages, but the fraction of resident CD163+ Tim4+ cells
remained stable.
Embryonic origin of tissue-resident CD163+ Tim4+
macrophages in omentum
To evaluate the ontogeny and homeostasis of the different
macrophage subsets in omentum during ID8 tumor develop-
ment, we prepared protected radiation chimeras using CD45.1
congenic C57BL/6 recipient mice. The abdomen of mice was
protected with lead shielding to avoid radiation-induced re-
placement of tissue-resident macrophages. Following irradia-
tion, we adoptively transferred bonemarrow cells from CD45.1 ×
CD45.2 F1 mice (CD45.1/.2), which allowed the distinction be-
tween host (CD45.1+) and donor cells (CD45.1+/CD45.2+) by flow
cytometry (Fig. 4 A). 5 wk after the bone marrow transplanta-
tion, chimerism was confirmed in blood by flow cytometry
Figure 3. Characterization ofmacrophage subsets in omentum by flow cytometry and confocal microscopy. (A) Flow cytometry analysis of the myeloid
cell compartment in omentum. Myeloid cells are gated as (i) Live, CD45.2+, singlets, Linneg (CD5, CD19, NK1.1, Ly6G, Siglec F), CD11b+, and subsequently
macrophages were gated as F4/80+, CD64+. Monocytes were gated as (ii) F4/80−, CD64−, CCR2+. F4/80−, CD64−, and CCR2− CD11b+ myeloid cells were
designated as other. F4/80+ CD64+ macrophages were further gated based on (iii) CD169 and Lyve-1 expression, and finally CD169hi Lyve-1+ cells were further
divided into four subpopulations based on (iv) CD163 and Tim4 expression. SSC-A, side scatter area. (B)Whole-mount imaging of FALCs (CD45, white; CD169+,
red; CD163+, green) in the omentum; scale bar: 100 µm. (C)Whole-mount imaging of FALCs (CD45, white; CD163+, green; Tim4+, red) in omentum; scale bar: 50
µm. (D) Flow cytometry analysis and relative distribution of CD11b+ myeloid cell populations shown in A, i–iii during tumor growth. (E) Flow cytometry analysis
and relative distribution of CD169hi Lyve-1+ macrophage subsets shown in A, iv during tumor growth. Whole-mount confocal imaging analysis is representative
of n = 4 in two independent experiments. Flow cytometric data are represented as mean ± SEM of n = 4 and are representative of two independent
experiments.
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Figure 4. Embryonic origin of tissue-resident CD163+ Tim4+ macrophages in omentum. (A) Analysis of macrophage ontogeny in ID8 tumor-bearing mice
using shielded chimeras; host CD45.1 congenic mice were placed in a protective lead shield with only the hind legs exposed, before irradiation at 9 Gy. The
following day, mice were reconstituted with donor bone marrow cells from CD45.1/.2 F1 mice. 5 wk after reconstitution, mice were injected with 106 ID8-Luc
cells i.p. At 8 wk after tumor injection, omentum was collected for analysis by flow cytometry. (B) Analysis of CD163 and Tim4 expression among CD169hi Lyve-1+
macrophages in omentum from naive and tumor-bearing chimeric mice. (C) Chimerismwas calculated as the proportion of CD45.1/.2+ CD169hi Lyve-1+ macrophages
relative to CD45.1/.2+ expression among Ly6Chi blood monocytes. Data are represented as mean ± SEM of n = 5, and statistically significant difference was
calculated using two-way ANOVA followed by Tukey post hoc test; ***, P < 0.001. (D and E) Flow cytometry analysis of Cx3Cr1-GFP expression in CD169hi
Lyve-1+ macrophages (P1–4; D) and CCR2+ monocytes (E). (F) Fate-mapping of Cx3Cr1-expressing monocytes in Cx3cr1-R26tdRFP mice inoculated with ID8-Luc
cells. Mice were injected with ID8-Luc i.p., and after 8 wk, 1 mg of tamoxifen was administered by oral gavage, and RFP expression was analyzed in CD169hi
Etzerodt et al. Journal of Experimental Medicine 6 of 22
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(Fig. S2 A) before mice were injected with ID8 cells. After an
additional 8 wk of tumor growth, omentum was harvested for
analysis. To track bone marrow–derived cells, CD45.1 and
CD45.2 expression by omental macrophages was analyzed and
normalized to blood monocytes. Chimerism within P3 (CD163−
Tim4−) and P4 (CD163− Tim4+) populations was, on average,
close to 100%, in both naive and tumor-bearing mice (Fig. 4, B
and C). In contrast, chimerism in P1 (CD163+ Tim4+) macro-
phages was close to zero, irrespective of tumor growth, while
the P2 (Tim4− CD163+) population showed ∼40% chimerism in
naive mice and complete chimerism in tumor-bearing mice
(Fig. 4, B and C). These data showed that CD163+ Tim4+ omental
macrophages (P1) were not replaced by bone marrow–derived
cells throughout the course of this experiment, which was >3
mo. However, P3 and P4 cells were completely replaced in both
steady state and during tumor development over this time
course, suggesting that these cells represent monocyte-derived
macrophages of limited life span. In contrast, CD163+ Tim4−
macrophages (P2) were only partially replaced over 3 mo at
steady state, although they showed complete replacement dur-
ing tumor growth. Therefore, these cells represent long-lived
monocyte-derived macrophages whose replacement is acceler-
ated during tumor development.
To verify the contribution of circulating monocytes to
omental TAMs, we next performed a fluorescent fate-mapping
experiment using mice expressing Cx3cr1-CreERT2
(Cx3cr1CreER) and a Rosa26-lox-STOP-lox(LSL)-tdRFP reporter
allele (Cx3cr1-R26tdRFP; Yona et al., 2013; Goossens et al., 2019).
In adult mice, Cx3cr1 is expressed by monocytes in blood and
omentum, but expression is decreased as monocytes mature into
macrophages (Fig. 4, D and E). To label monocytes during tumor
development, Cx3cr1-R26tdRFP mice were injected with ID8 cells,
and after 6 wk, mice were given a single dose of tamoxifen by
oral gavage to activate RFP expression in Cx3cr1+ cells. 10 d later,
RFP in omental macrophages was assessed by flow cytometry. As
expected, P3 and P4 populations weremost strongly labeled with
RFP under these conditions, whereas P2 macrophages were la-
beled to a lesser extent (Fig. 4 F). In contrast, there was minimal
labeling of CD163+ Tim4+ cells (P1; Fig. 4 F). These data are
consistent with a rapid replacement of P3 and P4 macrophages
by monocytes, while P2 cells are replaced with slightly slower
kinetics. However, in keeping with data from shielded chimera
experiments, there was very little replacement of P1 macro-
phages by Cx3Cr1-expressing precursors.
The experiments described above showed that CD163+ Tim4+
omental macrophages were not derived from bone marrow–
dependent monocyte precursors, suggesting that these tissue-
resident macrophages may be of embryonic origins. To evaluate
the potential embryonic origins of these cells, we performed a
fate mapping experiment with Cx3cr1CreER mice in utero, since
Cx3cr1 is expressed in both embryonic macrophage precursors
and fetal monocytes (Yona et al., 2013). Cx3cr1-R26YFP embryos
were pulse-labeled with tamoxifen at E16.5, and YFP expression
in macrophages from omentum was subsequently analyzed by
flow cytometry at 8 wk of age (Fig. 4 G). After normalization of
YFP+ cells to microglia to assess labeling efficiency (Fig. S2 C),
we observed that ∼20% of P1 macrophages (CD163+ Tim4+) in
adult omentum were YFP+ (Fig. 4, H and I), indicating an em-
bryonic origin for these cells. In contrast, very few YFP+ cells
were detected in the P2 (CD163+ Tim4−), P3 (CD163− Tim4−), and
P4 (CD163− Tim4−) populations (Fig. 4, H and I), demonstrating
that these cells were not derived from embryonic progenitors
or were most likely replaced by monocyte-derived cells in
the adult.
Collectively, these experiments show that CD163+ Tim4+
macrophages in omentum are uniquely independent of bone
marrow–derived monocytes both in steady state and during
tumor growth and are thus likely to maintain themselves locally
by self-renewal. Furthermore, at least a significant proportion of
these cells are of embryonic origin.
CD163+ Tim4+ tissue-resident macrophages express a unique
transcriptional profile
To evaluate the impact of tumor growth on the phenotype of
different macrophage subsets in omentum, we performed
transcriptional profiling of cells sorted by flow cytometry at
steady state and at different time points after seeding with tu-
mor cells. We isolated P1, P2, and P3 macrophages by FACS from
naive omentum and at 5 or 10 wk after injection of ID8 cells
(Fig. 5 A) and prepared sequencing libraries directly from snap-
frozen cell pellets. Libraries were sequenced to an average read
depth of 42.7 million reads per sample. Unfortunately, the RNA
yield in P4 macrophages was too low to generate sequencing
libraries. A heatmap showing the 5,000 most-variable genes in
the dataset is shown in Fig. S3 A. Initial analysis confirmed an
overlap in the expression levels of the markers highlighted in
the scRNAseq analysis; P1 macrophages coexpressing Lyve-1,
CD163, and Tim4; and P2 macrophages expressing Lyve-1 and
CD163, but not Tim4. However, P3 macrophages expressed very
low levels of all three markers (Fig. S3 B). To analyze the rela-
tionship between the different macrophage populations, we
performed a principal component analysis (PCA) combined with
network analysis to show the n nearest neighbors. This analysis
showed that the transcriptional profile of CD163+ Tim4+ resident
macrophages (P1) did not undergo major changes during tumor
growth, as all samples from this population clustered closely
together (Fig. 5 B). Interestingly, the long-lived monocyte-
derived CD163+ Tim4− macrophages (P2) were closely related
to CD163+ Tim4+ resident macrophages (P1) at steady state, but
in tumor-bearing mice, they became more closely aligned to P3
(Fig. 5 B), which likely reflects the increased replacement of P2
macrophages by monocyte-derived cells during tumor growth
(Fig. 4, B and C). To further analyze the transcriptional changes
between these three major subsets in established tumors, we
Lyve-1+ macrophages 10 d later. Data are represented as mean ± SEM of n = 4. (G) Analysis of CD169hi Lyve-1+ macrophage ontogeny by pulse-labeling of
Cx3Cr1−R26YFP embryos with tamoxifen at E16.5. (H)Omentumwas harvested and analyzed by flow cytometry 8 wk after birth. (I) The percentage of YFP+ cells
was calculated relative to YFP+ microglia. Data are represented as mean ± SEM of n = 6. All data are representative of two independent experiments.
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Figure 5. CD163+ Tim4+ tissue-resident macrophages express a unique transcriptional profile. (A) Gating strategy for cell sorting of P1, P2, and P3
populations of omental macrophages from naive (n = 2) and tumor-bearingmice at 5 and 10wk after injection of ID8 cells (n = 4). 500 cells were sorted for each
population and subjected to bulk RNAseq analysis. (B) PCA and network analysis of variable gene expression in P1, P2, and P3 macrophages. PCA analysis was
performed on normalized data (mean = 0, and variance = 1), generating a correlation-based PCA plot. Network analysis connects k nearest neighbors (k = 3)
based on similarity calculated by Pearson correlation. (C) Heatmap showing hierarchical clustering of the 5,000most DEGs for each of the three populations at
10 wk of tumor growth. DEGs were identified by pairwise comparison with a cut-off of Padjusted > 0.01. (D) SOMs of identified DEGs using the Kohonen package
for R. The SOM analysis found 16 single SOMs that were subsequently grouped by hierarchical clustering to identify population-specific clusters (clusters 1–7).
The magnitude of the pie slices indicates the relative proportions of genes enriched in P1 (green), P2 (brown), and P3 (blue) within the SOM. (E) ClusterProfiler
enrichment analysis against the GO database on SOM clusters 1–7. Only clusters with significantly enriched pathways are visualized. Libraries were prepared
from two independent experiments with n = 2 and sequenced on the same flow cell for a total of four biological replicates. ERAD, endoplasmic reticulum–
associated protein degradation; pos, positive.
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extracted DEGs by pairwise and grouped comparisons of P1, P2,
and P3 at 10 wk of tumor growth (Fig. 5 C). We then performed a
self-organizing map (SOM) clustering analysis to identify clus-
ters of genes enriched in either a single population or a group of
populations (Fig. 5 D). In the SOM clustering analysis, genes
with a similar expression profile are first organized into SOMs.
Within thesemaps, a pie chart depicts the relative enrichment of
genes in the three populations analyzed (P1, P2, and P3), and the
size of the pie slices reflects the gene enrichment. SOMs that are
similar are then grouped together, generating clusters of SOMs
with a comparable gene enrichment profile. This analysis gen-
erated 16 different SOMs that were subsequently grouped in 7
distinct clusters. Cluster 2 was enriched in P1, cluster 6 in P2,
and cluster 5 in P3. Cluster 3 contained genes enriched in both P1
and P2, and cluster 7 was enriched in both P2 and P3. We then
used ClusterProfiler enrichment analysis and the Gene Ontology
(GO) database for the different SOM clusters to identify bio-
logical processes enriched in the different populations. This
analysis revealed multiple enriched processes in clusters 2, 3, 5,
and 6; the 15 most significant terms are shown in Fig. 5 E. Of
particular interest, positive regulation of JAK-STAT signaling
was uniquely enriched in CD163+ Tim4+ macrophages (P1,
cluster 2; Fig. S5 A), whereas pathways related to angiogenesis,
blood vessel development, and tissue remodeling were shared
between CD163+ populations (P1 and P2, cluster 3; Fig. S5, B and
C). Interestingly, the STAT pathway is part of the self-renewal
gene regulatory network in macrophages (Soucie et al., 2016), in
line with the ability of these cells to maintain themselves inde-
pendently of bone marrow–derived monocytes. In addition, the
pathways and processes enriched in both CD163+ populations (P1
and P2) have previously been linked with tumor-promoting
functions of TAMs (Noy and Pollard, 2014). In contrast, path-
ways associated with T cell differentiation were uniquely asso-
ciated with P3 (cluster 5; Fig. S5 D). This analysis suggested a
functional diversification of omental macrophage subsets in the
context of tumor growth.
Specific depletion of CD163+ Tim4+ macrophages prevents
metastatic spread of ovarian cancer
Next, we sought to analyze the specific contributions of omental
macrophage subsets to disease progression in our model. Initial
experiments showed that tumor development and accumulation
of malignant ascites were not affected in Ccr2−/− mice (Fig. S4,
A–D). These mice have impaired recruitment of monocyte-
derived cells, suggesting a redundant function of CCR2-
dependent monocyte-derived macrophages in disease progression.
To assess the specific contribution of CD163+ Tim4+ tissue-
resident macrophages (P1), we generated transgenic mice that
exclusively express DTR in CD163+ macrophages (Cd163-
Csf1rDTR; Etzerodt et al., 2019); Cd163-iCre knock-in mice
(Cd163iCre) were crossed with transgenic mice expressing
an LSL-DTR cassette under control of the Csf1r-promoter
(Tg(Csf1r-LSL-DTR)). Flow cytometry analysis of omentum
from Cd163-Csf1rDTR mice 24 h after a single injection of dip-
theria toxin (DT; 4 ng/kg) confirmed the specific ablation of
CD163+ P1 and P2 macrophages (Fig. S4, E–G). However, 6 d
after DT treatment, monocyte-derived P2 macrophages were
completely restored, while resident P1 macrophages remained
absent (Fig. S4, E–G). In addition, there was also a complete
recovery of CD163+ peritoneal macrophages 6 d after DT
treatment (Fig. S4 H). Thus, this approach allows the selective
ablation of resident CD163+ P1 macrophages in omentum and
the opportunity to assess their unique contribution toward
tumor progression. We treated cohorts of Cd163-Csf1rDTR and
Cre-negative littermate controls (Csf1rLSL-DTR) with DT and 6 d
later injected ID8 cells i.p. After 10 wk, omentum was collected
for analysis by flow cytometry, and tumor progression was
assessed (Fig. 6 A). At this time point, P1 macrophages re-
mained depleted in omenta from Cd163-Csf1rDTR mice while all
other populations were unchanged (Fig. 6, B and C). Interest-
ingly, although tumor seeding of the omentum was unaffected
(Fig. 6 D), Cd163-Csf1rDTR mice showed a significant reduction
in ascitic tumor cells (Fig. 6 E) and reduced ascites (Fig. 6 F).
Moreover, metastases to the diaphragm were significantly re-
duced in Cd163-Csf1rDTR mice (Fig. 6, G and H). These data
suggested that tissue-resident CD163+ Tim4+ macrophages in
the omentum contributed significantly to the metastatic spread
of ovarian cancer cells and the development of invasive disease.
To further substantiate the role of CD163+ macrophages in
tumor progression, we used CD163-targeted cytotoxic lipid
nanoparticles (LNPs) to therapeutically deplete CD163+ macro-
phages in tumor-bearingmice (Etzerodt et al., 2019). These LNPs
contain 5% polyethylene glycol (PEG; molecular weight, 2,000 g/
mol) in the lipid bilayer, which minimizes nonspecific phago-
cytic uptake, and are loaded with the cytotoxic drug doxorubicin
(dxr) to kill target cells. LNPs are targeted specifically to CD163-
expressing cells by conjugation of an anti-CD163 monoclonal
antibody to PEG (Etzerodt et al., 2012). To achieve therapeutic
depletion of CD163+ macrophages, mice were injected with ID8
cells and 5 wk later treated i.v. twice a week for 5 wk with ve-
hicle, empty CD163-targeted LNPs (αCD163-ctrl), or dxr-loaded
LNPs (αCD163-dxr; Fig. 6 I). In vivo bioluminescent imaging
showed that continuous depletion of CD163+ cells after αCD163-
dxr treatment resulted in a significant reduction of overall tu-
mor burden in the abdomen (Fig. 6 J). As expected, sustained
depletion of CD163+ cells led to the specific loss of both P1 and P2
macrophages in omentum (Fig. 6 K), which was accompanied by
a significant decrease of tumor burden in both omentum and
ascites (Fig. 6, L–N), suggesting that the additional absence of
monocyte-derived CD163+ macrophages (P2) contributed to re-
duced tumor growth in the omentum (Fig. 6 L), which was not
observed when only tissue-resident CD163+ Tim4+ macrophages
(P1) were depleted (Fig. 6 D).
Ovarian cancer cells in ascites acquire CSC characteristics
Ascitic tumor development and peritoneal metastases indicate a
particularly poor prognosis for ovarian cancer patients. Our
studies showed a long latency in ascitic tumor development and
peritoneal spread of ID8 cells after seeding the omentum, and
omentectomy prevented development of ascitic disease (Fig. 1),
suggesting that the omentum represents a key premetastatic
niche. In addition, the studies described above showed that
tissue-resident macrophages in omentum contributed signifi-
cantly to the accumulation of ascitic cells and the development
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Figure 6. Specific depletion of CD163+ Tim4+ tissue-resident macrophages preventsmetastatic spread of ovarian cancer. (A) Cohorts of Cd163-Csf1rDTR
or control mice (Csf1rLSL-DTR) were injected with 4 ng/kg DT 6 d before transplantation with ID8 cells. Mice were analyzed for depletion of macrophages and
effects on tumor growth at 10 wk. (B and C) Flow cytometry analysis of CD163hi Lyve-1+ macrophages in omentum of Cd163-Csf1rDTR and Csf1rLSL-DTR mice 10
wk after injection of ID8 cells. (D–F) Omentum weight (D), total tumor cells in ascites (E), and ascites volume (F) in Cd163-Csf1rDTR and Csf1rLSL-DTRmice treated
with DT. (G and H) Ex vivo bioluminescence analysis of metastases on the diaphragm of Cd163-Csf1rDTR and Csf1rLSL-DTR; scale bar: 0.5 cm. Data are represented
as mean ± SEM of n = 7, and statistically significant difference was calculated using Mann-Whitney U test; *, P < 0.05; **, P < 0.01; ***, P < 0.001.
(I) Therapeutic depletion of CD163+ macrophages; mice were injected with ID8 cells and after 5 wk randomized into groups and treated with dxr-loaded
αCD163-LNPs (αCD163-dxr), empty αCD163-LNPs (αCD163-ctrl), or PBS alone twice a week for 5 wk. (J) Tumor burden monitored by in vivo bioluminescent
imaging. Data are represented as mean ± SEM of n = 6, and statistically significant difference was calculated using two-way ANOVA followed by Tukey post hoc
test; *, P < 0.05; ***, P < 0.001. (K) Flow cytometry analysis of P1–P4 macrophages in omentum after therapeutic depletion of CD163+ cells. (L–N) Omentum
weight (L), total tumor cells in ascites (M), and ascites volume (N). Data are represented as mean ± SEM of n = 6, and statistically significant difference was
calculated using Kruskal-Wallis one-way ANOVA followed by Dunn’s multiple comparisons test; *, P < 0.05; **, P < 0.01; ***, P < 0.001. All data are rep-
resentative of three independent experiments.
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of invasive disease (Fig. 6). To further explore the phenotype of
ascitic ID8 cells and define the mechanisms behind this invasive
transition, we performed transcriptomic analysis of cultured
ID8 cells and tumor cells isolated from malignant ascites 11 wk
after transplantation (ID8-A11). ID8 and ID8-A11 cells were sor-
ted by flow cytometry, and RNAseq libraries were prepared
directly from frozen cell pellets. To identify meaningful bio-
logical processes that are affected in ID8-A11 cells comparedwith
parental ID8 cells, we performed a GO term-based gene set en-
richment analysis (GSEA; Fig. S5 E); GO terms are represented
by nodes that are colored according to the normalized enrich-
ment score. GO terms that share DEGs are grouped together,
generating clusters, thus indicating common biological pro-
cesses. With this analysis, we found clusters of GO terms up-
regulated in ID8-A11 cells that represent biological processes
often associated with metastatic tumor cells, including drug
metabolism, epithelial cell migration, organization of cell junc-
tions, and organ development (Fig. S5 E, red). In contrast,
clusters of GO terms that were down-regulated in ID8-A11 cells
weremainly linkedwith biological processes associated with cell
division such as cytokinesis, cell cycle, DNA repair, and repli-
cation (Fig. S5 E, blue). To further explore these pathways, we
performed GSEA; in accordance with a metastatic phenotype,
GSEA showed a positive enrichment of gene sets associated with
EMT and down-regulation of genes associated with cell cycle
and cell division (Fig. S5 F). The inverse enrichment of EMT
pathways versus cell division, coupled with the up-regulation of
WNT, NOTCH, and STAT3 signaling (Fig. S5 F), suggested that
ID8-A11 cells may have acquired a CSC-like phenotype. Ascitic
tumor cells with CSC characteristics have been associated with
advanced human ovarian cancer, where they form multilayered
spheroid structures (Bapat et al., 2005). To assess the CSC-like
phenotype of ascitic ID8 cells compared with ID8 cells in
omentum, we next compiled a list of genes that were reported as
biomarkers of ovarian CSCs (Table S1) and analyzed their ex-
pression in ascitic ID8 cells (ID8-A11) compared with cells in the
omentum (ID8-OM). This analysis confirmed an up-regulation
of most CSC markers in ascitic ID8 cells (Fig. 7 A, Cluster III). In
addition, we established a panel of cell-surface CSCmarkers and
measured their expression by flow cytometry. In agreement
with gene expression analysis, ID8-A11 cells showed increased
expression of a number of surface markers for CSCs, including
CD44, CD54, CD55, CD106, and CD117, as comparedwith ID8 cells
in omentum (Fig. 7 B). As mentioned above, spheroid formation
is a functional characteristic of CSCs, as is the increased activity
of aldehyde dehydrogenase (ALDH; Kim et al., 2018). In contrast
to cultured ID8 cells, ascitic ID8-A11 cells rapidly formed sphe-
roids in vitro (Fig. 7, C and D). In addition, flow cytometry
analysis of ALDH activity using the Aldefluor assay showed in-
creased ALDH activity in ID8-A11 cells (Fig. 7 E). Finally, ac-
quisition of CSC characteristics is associated with increased
tumor-initiating potential and metastatic spread. We therefore
injected cohorts of mice with either ID8 or ID8-A11 cells and
followed tumor burden and spread in vivo using biolumines-
cence. The overall tumor burden in mice injected with ID8-A11
cells was already significantly increased after 20 d, whereas
parental ID8 cells still had not established significant tumors
(Fig. 7 F). Moreover, when tumors did establish in mice injected
with ID8 cells, these were restricted to the omentum, whereas
ID8-A11 cells had spread throughout the peritoneal cavity
(Fig. 7 G). This was further substantiated in ex vivo analysis that
showed increased growth of ID8 cells in omentum at this time
point and the absence of ascites, whereas ID8-A11 cells showed
reduced growth in omentum and generated considerable ascitic
tumor growth (Fig. 7, H and I). These studies demonstrated that
the transition to invasive disease in this model was associated
with the acquisition of CSC characteristics by ascitic tumor cells.
CD163+ Tim4+ tissue-resident macrophages promote the
CSC-like phenotype of ovarian cancer cells
We next evaluated the impact of tissue-resident macrophages in
omentum on the acquisition of CSC characteristics by ascitic ID8
cells. CD163+ macrophages in the omentum were depleted by
three consecutive injections of CD163-targeted cytotoxic LNPs
(αCD163-dxr) on days 1, 3, and 5, and control mice were injected
with either vehicle or empty LNPs (αCD163-ctrl). Monocyte-
derived CD163+ macrophages (P2) were then allowed to re-
cover before injection of ID8 cells on day 8, and the development
of invasive disease was analyzed at 10 wk (Fig. 8 A). Specific
depletion of resident CD163+ Tim4+ macrophages (P1) in omen-
tum was confirmed by flow cytometry (Fig. 8, B and C), as was
the impaired development of invasive disease, including the
number of ascitic tumor cells and peritoneal metastases (Fig. 8,
D–G). To evaluate the impact on CSC-like phenotype in ID8 cells,
we next analyzed the expression of our CSC marker panel by
flow cytometry on ascitic ID8 cells from control-treated mice
and after depletion of resident omental macrophages (Fig. 7 B
and Table S1). We then conducted an unsupervised gating
analysis and dimensionality reduction using t-distributed sto-
chastic neighbor embedding (tSNE). Samples corresponding to
individual treatment groups were subsequently gated out and
replotted as individual tSNE plots (Fig. 8 H). This analysis
showed that ascitic tumor cells from αCD163-dxr–treated mice,
specifically lacking resident CD163+ Tim4+ macrophages in the
omentum, clearly separated from ascitic tumor cells in control
mice (Fig. 8 H, green versus red/blue, respectively). Subsequent
color mapping of the staining intensity for each of the CSC
markers revealed a loss of tumor cells expressing CD54, CD55,
CD106, and CD117 in αCD163-dxr–treated mice (Fig. S5 G). The
reduced frequency of CD54-, CD55-, CD106-, and CD117-
expressing cells was subsequently confirmed by manual gat-
ing. This showed that in control mice >60% of ascitic ID8 cells
expressed CSC markers, which was reduced to <20% upon de-
pletion of resident CD163+ Tim4+ macrophages in the omentum
(Fig. 8 I). Thus, the specific depletion of resident omental mac-
rophages resulted in reduced accumulation of ascitic tumor cells
with a CSC-like phenotype. The acquisition of CSC character-
istics is frequently associated with EMT (Nieto et al., 2016), and
our previous transcriptomic analysis of ascitic ID8 cells showed
an up-regulation of EMT-associated genes (Fig. S5 F). To confirm
these data, we analyzed the expression of transcription factors
(TFs) known to drive either EMT or the reverse process known
as mesenchymal-to-epithelial transition (MET) in ID8-A11 cells.
This analysis confirmed an increased gene expression of TFs
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Figure 7. Ovarian cancer cells in ascites acquire CSC characteristics. (A) Heatmap showing expression of CSC markers in omental ID8 cells (ID8-OM) and
ID8 cells from ascites (ID8-A11); see Table S1 for details. (B) Flow cytometry analysis of CSC surface markers on ascitic ID8-A11 cells compared with ID8 cells in
omentum (ID8-OM). (C and D) Spheroid formation assay comparing cultured ID8 and ID8-A11 cells; 4 × 104 cells were seeded in ultra-low-adherence 96-well
plates, and formation of spheroids was assessed with a wide-field microscope. (E) Analysis of ALDH activity in ID8 and ID8-A11 cells by flow cytometry using
the Aldefluor assay. ALDH+ cells were gated using DEAB-treated cells as negative control (left), and relative ALDH activity was calculated by measuring the
median fluorescence intensity of Aldefluor. Data are represented as mean ± SEM of n = 5 (ID8) or n = 8 (ID8-A11), and statistically significant difference was
calculated using Mann-Whitney U test; *, P < 0.05; **, P < 0.01. (F) Analysis of tumorigenic potential of ID8 and ID8-A11 cells in vivo; total tumor burden was
monitored by in vivo bioluminescence imaging. Data are represented as mean ± SEM of n = 6, and statistically significant difference was calculated using two-
way ANOVA followed by Tukey post hoc test; **, P < 0.01; ****, P < 0.0001. (G) Representative images of tumor localization at 30 d after injection of parental
ID8-Luc and ID8-A11 cells; scale bar: 1 cm. (H and I) Ex vivo analysis of tumor burden in omentum (H) and ascites (I) at 30 d after transplantation of ID8-Luc or
ID8-A11 cells. Data are represented as mean ± SEM of n = 6 (ID8) or n = 5 (ID8-A11), and statistically significant difference was calculated usingMann-Whitney U
test; **, P < 0.01. All data are representative of two independent experiments.
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Figure 8. CD163+ Tim4+ tissue-resident macrophages promote the CSC-like phenotype of ovarian cancer cells. (A) Specific depletion of CD163+ Tim4+
(P4) macrophages using dxr-loaded αCD163-LNPs (αCD163-dxr); mice were injected i.p. with 1 mg/kg αCD163-dxr or controls (empty αCD163-LNPs or PBS) on
days 1, 3, and 5, before injection of ID8-Luc cells on day 8. (B and C) Flow cytometry analysis of CD163hi Lyve-1+ macrophages in omentum at 10 wk after
prophylactic treatment with αCD163-dxr. Data are represented as mean ± SEM of n = 5 (PBS, αCD163-LNP) or n = 6 (αCD163-dxr), and statistically significant
difference was calculated using Kruskal-Wallis one-way ANOVA followed by Dunn’s multiple comparisons test; *, P < 0.05; **, P < 0.01. (D–F) Omentum
weight (D), total tumor cells in ascites (E), and ascites volume (F) at 10 wk after prophylactic treatment with αCD163-dxr. (G) Ex vivo bioluminescence analysis
of metastases on the diaphragm. Data are represented as mean ± SEM of n = 8, and statistically significant difference was calculated using Kruskal-Wallis one-
way ANOVA followed by Dunn’s multiple comparisons test; *, P < 0.05; **, P < 0.01. (H) tSNE map of concatenated fcs files from flow cytometry analysis of
tumor cells from ascites after prophylactic treatment with αCD163-dxr. tSNE parameters were computed on expression levels of CSC markers (CD44, CD54,
CD55, CD106, CD117, CD140a, and EpCam), and individual sample files were color-coded according to treatment group (PBS, blue; αCD163-ctl, red; αCD163-
dxr, green; n = 8). This analysis identified distinct clusters from control-treated mice (PBS or αCD163-LNP; C1, black) and αCD163-dxr–treated mice (C2, gray).
Expression of the individual CSC markers was subsequently visualized by heatmap statistics in a tSNE map of the concatenated samples within C1 (PBS or
αCD163-LNP) and C2 (αCD163-dxr; right). (I) Flow cytometry analysis identifying the proportion of malignant cells expressing specific CSC markers: CD54,
CD55, CD106, and CD117. See Fig. S5 G for the gating strategy. Data are represented as mean ± SEM of n = 8, and statistically significant difference was
calculated using Kruskal-Wallis one-way ANOVA followed by Dunn’s multiple comparisons test; **, P < 0.01. (J) Gene expression analysis of Gata3, Stat3,
Wnt5a, and Mertk in tumor cells from omentum after specific depletion of CD163+ Tim4+ (P1) macrophages, as described in A. dCT, delta cycle threshold. Data
are represented as mean ± SEM of n = 6, and statistically significant difference was calculated using Kruskal-Wallis one-way ANOVA followed by Dunn’s
multiple comparisons test; *, P < 0.05; **, P < 0.01. A–G are representative of three independent experiments, whereas H–J are representative of two in-
dependent experiments.
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driving EMT (e.g., Zeb2), whereas TFs involved in MET were
down-regulated (e.g., Gata3; Fig. S5 H). Interestingly, Gata3
alone was recently shown to be sufficient to reverse EMT and
inhibit metastases in breast and colon cancer (Yan et al., 2010;
Yang et al., 2017). Since EMT has been suggested to precede the
acquisition of CSC characteristics, we evaluated the expression
of EMT/MET regulators in ID8 cells from omentum after de-
pletion of CD163+ Tim4+ resident macrophages. Mice were
treated as described above, ID8 tumor cells were isolated from
the omentum, and expression of EMT- and MET-associated TFs
was analyzed. We observed a significant increase in gene ex-
pression of Gata3 in ID8 cells from omentum after depletion of
resident macrophages, which was accompanied by decreased
expression of Stat3, Wnt5a, and Mertk (Fig. 8 J), all positive
regulators of EMT and CSC phenotype.
In summary, these experiments showed that the acquisition
of EMT and CSC characteristics by ID8 cells and the develop-
ment of invasive disease are promoted by the presence of resi-
dent CD163+ Tim4+ macrophages in omentum.
Discussion
The vast majority of cancer-related deaths are due to the de-
velopment of metastatic disease. Themetastatic spread of cancer
can be described according to two basic models. The predomi-
nant linear model dictates a stepwise progression of primary
tumors before dissemination of fully metastatic malignant cells.
However, the parallel model accounts for the early dissemina-
tion of cancer cells and the formation of distant metastases that
develop in parallel with the primary tumor. While there has
been extensive research into the stepwise progression of pri-
mary tumors toward a metastatic phenotype, relatively little is
known about the role of cells that form the premetastatic niche
for disseminated cancer cells and their involvement in the
metastatic spread of disease. Given that macrophages populate
all adult tissues and the proven role of TAMs in promoting in-
vasion and metastasis in experimental models (Noy and Pollard,
2014), it is likely that resident macrophages form an important
component of the tissue niche for the malignant progression of
disseminated cancer cells.
It had previously been assumed that TAMs are mainly
monocyte derived (Lahmar et al., 2016; Yang et al., 2018), until
several recent studies showed that macrophages of embryonic
origin can persist in tumors from experimental models and may
have distinct contributions toward tumor progression (Zhu
et al., 2017; Loyher et al., 2018). However, these studies were
limited by the lack of specific markers to distinguish TAM
subsets on the basis of their origins and tools to specifically
target these subsets. For example, Zhu et al. (2017) used para-
biosis and fluorescent fate-mapping tools in a model of pan-
creatic ductal adenocarcinoma to identify a population of
MHCIIlo TAMs of embryonic origin that were maintained in-
dependently of blood monocytes. However, to assess the con-
tribution of these cells to tumor growth, the authors used an
aggressive pan-targeting strategy combining both clodronate
liposomes and CSF1 blockade to efficiently deplete all tissue-
resident macrophages.
Here, we studied the origins and function of macrophage
subsets in a model of metastatic ovarian cancer, using a novel
intersectional transgenic approach and antibody-targeted cyto-
toxic liposomes to specifically deplete CD163+ macrophages. We
describe how tissue-resident CD163+ macrophages in omentum
play a specific role in the malignant progression of ovarian
cancer and the development of invasive disease. We showed that
ovarian cancer cells injected into the peritoneal cavity infiltrate
the omentum in the vicinity of FALCs and in close contact with
resident CD163+ macrophages. Using single cell transcriptomics,
flow cytometry, and whole-mount imaging, we identified dis-
tinct subsets of CD169+ Lyve-1+ mature macrophages in omen-
tum based on their expression of CD163 and Tim4. CD163 has
been used extensively as a marker of tissue macrophages in
humans, where the frequency of CD163+ TAMs shows a striking
correlation with poor clinical outcome in a range of cancers
(Komohara et al., 2014). Conversely, few studies have addressed
the expression of Tim4 in human macrophages. Recent studies
have shown that Tim4 is expressed by a range of long-lived
tissue-resident macrophages in mice, including Kupffer cells
(Scott et al., 2016), large peritoneal macrophages (Rosas et al.,
2014), and gut and cardiac macrophages (Dick et al., 2019; De
Schepper et al., 2018), and is thus emerging as a marker of
tissue-resident macrophages with potential for self-renewal.
When analyzing the ontogeny of CD169+ Lyve-1+ macrophages in
omentum, we found that Tim4 expression alone did not distin-
guish long-lived cells, since Tim4+ CD163− macrophages (P4)
were monocyte derived and rapidly replaced by bone marrow–
derived cells. However, CD163+ Tim4+ (P1) macrophages were
uniquely independent of bone marrow–derived monocytes in
the adult, in both steady state and during tumor development,
and at least a proportion of these cells were shown to be of
embryonic origin. In contrast, CD163+ Tim4− macrophages (P2)
were relatively long lived at steady state, compared with CD163-
negative cells, but were quickly replaced by monocyte-derived
cells after tumor initiation. Transcriptomic analysis revealed a
close relationship between CD163+ P1 and P2 macrophages at
steady state, but during tumor development, monocyte-derived
Tim4-negative P2 macrophages significantly diverged from
Tim4+ P1 cells and became more similar to short-lived CD163-
negative monocyte-derived cells (P3). In fact, the phenotype of
CD163+ Tim4+ resident macrophages in omentum was remark-
ably stable during tumor progression, suggesting that these cells
maintain a level of tissue imprinting that is lost from more
short-lived cells. Transcriptomic analysis of these different TAM
subsets suggested functional diversification during tumor
growth. Resident CD163+ Tim4+ (P1) macrophages showed a
unique enrichment of pathways regulating JAK-STAT signaling,
also previously linked with macrophage self-renewal (Soucie
et al., 2016). However, other pathways previously associated
with tumor-promoting functions, such as angiogenesis, blood
vessel development, and tissue remodeling, were shared be-
tween both monocyte-derived and resident CD163+ populations
(P1 and P2).
Prophylactic depletion of CD163+ macrophages, allowing re-
covery of monocyte-derived CD163+ Tim4− cells, revealed an
important and specific role for resident CD163+ Tim4+ omental
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macrophages in the development of invasive disease. However,
therapeutic depletion of both P1 and P2 CD163+ TAMs using
cytotoxic liposomes had a major impact on both primary tumor
growth and invasive disease, suggesting that monocyte-derived
and tissue-resident CD163+ TAMs have distinct roles in disease
progression. We recently showed that depletion of monocyte-
derived CD163+ TAMs in a mouse melanoma model led to a
T cell–mediated regression of tumor growth (Etzerodt et al.,
2019), which may also account for the observed reduction in
omental tumor burden upon depletion of monocyte-derived
CD163+ macrophages in this model.
Macrophages play important roles in organogenesis and tis-
sue remodeling (Pollard, 2009) and have been shown to affect
epithelial cell plasticity and stimulate tissue stem cells
(Chakrabarti et al., 2018; Lee et al., 2018). The acquisition of
stem-like characteristics by cancer cells (CSCs) has been sug-
gested to promote tumor progression and metastasis (Kreso and
Dick, 2014). CSCs show increased anchorage-independent sur-
vival and high levels of resistance to chemotherapy or radio-
therapy and thus havemajor implications for disease recurrence
from disseminated tumor cells. EMT is also frequently associ-
ated with CSCs and accounts for the acquisition of migratory
and invasive properties (Nieto et al., 2016). Several reports have
shown that ascitic tumor cells from late-stage ovarian cancer
patients show CSC-like characteristics (Lupia and Cavallaro,
2017; Bapat et al., 2005), which may explain the rapid pro-
gression of late-stage disease in these patients and the high
frequency of disease recurrence. When analyzing the tran-
scriptome of ascitic tumor cells in our model, we found a
significant enrichment of pathways associated with CSCs and
EMT. Interestingly, not only did the specific depletion of CD163+
Tim4+ resident macrophages in omentum decrease the forma-
tion of malignant ascites, it also reduced the frequency of CSCs
among the few ascitic tumor cells that did accumulate. Analysis
of tumor cells in the omentum showed that genes associated with
regulation of EMT and CSCs, namely Stat3 (Abubaker et al.,
2014), Wnt5a (Ford et al., 2014), and Mertk (Jung et al., 2016),
were down-regulated in tumor cells when CD163+ Tim4+ mac-
rophages were absent, whereas Gata3, a negative regulator of
EMT, was up-regulated. In this regard, it is of particular interest
that clustering analysis showed that CD163+ Tim4+ macrophages
were enriched for genes associated with positive regulation of
the JAK-STAT pathway. This included IL6, EPO, and prolactin, all
of which activate STAT3 and have previously been shown to
promote EMT and the acquisition of CSC characteristics in
ovarian cancer (Solar et al., 2008; Wang et al., 2018; Levina et al.,
2009). Future studies will elucidate the molecular basis of the
dialog between tissue-resident macrophages and ovarian cancer
cells leading to the up-regulation of JAK-STAT signaling. Given
the conserved role of these pathways in EMT and CSCs, these
axes of interaction could be relevant to other cancers associated
with the dissemination of premalignant or dormant cancer cells.
Of note, tissue-resident macrophages of embryonic origin also
dominate the adult mammary gland in the mouse (Jäppinen
et al., 2019), and recent studies have shown an important role
for mammary gland macrophages in regulating the phenotype of
basal stem cells (Chakrabarti et al., 2018).
In summary, our data show that tissue-resident macrophages
in omentum play a specific role in the malignant progression of
disseminated tumor cells and the development of invasive dis-
ease in a mouse model of metastatic ovarian cancer. These
studies add significantly to our understanding of TAM hetero-
geneity and the specific contribution of different macrophage
subsets to disease progression. The axes of interaction between
tissue-resident macrophages and cancer cells could represent
important new therapeutic targets, not only in ovarian cancer
but also other cancers where the development of CSCs can have
a disastrous impact on disease prognosis.
Materials and methods
Mouse breeding, omentectomy, and ovarian cancer model
Tg(Csf1r-LSL-HBEGFmCherry; Schreiber et al., 2013), Ro-
sa26LSL-YFP, Cx3Cr1CreER, and Cx3C1rGFP/+ were obtained from
the Jackson Laboratory. C57BL/6J mice were obtained from
Janvier Labs. Ccr2−/− mice and Rosa26LSL-tdRFP mice were gifts
from Bernard Malissen (Centre d’Immunologie de Marseille-
Luminy [CIML], Marseille, France). Cd163iCre mice were gen-
erated from modified embryonic stem cells on a C57BL/6
background as described (Etzerodt et al., 2019). In brief, a FlpO-
NeoR cassette encoding IRES-iCre was inserted in the 39UTR of
the CD163 gene using homologous recombination and used to
generate chimeric mice that were subsequently crossed to Flp
deleter mice to facilitate removal of NeoR cassette. Omentec-
tomy and sham surgery were performed on mice under general
anesthesia using 87.5 mg/kg ketamine and 12.5 mg/kg xylazine
injected i.p. Laparotomy was performed through a 1-cm inci-
sion in the region of the stomach, and omentum was carefully
removed. The abdominal wall was then closed in two layers
with surgical suture. Sham surgery was performed as described
above with the omentum carefully lifted before being placed
back in the abdominal cavity. To mimic peritoneal spread of
epithelial ovarian cancer, 106 ID8-Luc cells were injected i.p. in
500 µl of sterile PBS (pH 7.4). Tumor burden was estimated
weekly by injecting mice i.p. with 100 mg/kg d-luciferin fol-
lowed by in vivo bioluminescence imaging using an IVIS
Spectrum imager (PerkinElmer). For visualizing infiltration of
ID8-cells in omentum, ID8 cells were prelabeled with a
Qtracker 705 cell labeling kit (Thermo Fisher Scientific) before
i.p. injections in accordance with the manufacturer’s in-
structions. For therapeutic treatment with LNPs, mice were
injected with 100 µl of LNPs (1 mg/kg dxr) by retroorbital in-
jection starting from 5 wk after i.p. injection of 106 ID8-Luc
cells. For prophylactic treatment with LNPs or DT, mice were
injected i.p. with either 200 µl of LNPs (1 mg/kg dxr) or 200 µl
of DT (4 ng/kg) starting from 6 d before inoculation of tumor
cells. All mice were euthanized at the indicated times, and
peritoneal lavages and tissues were collected for cytometric
analysis or imaging analysis. Briefly, 3 ml of ice-cold PBS with
2 mM EDTA, pH 8.0 was injected i.p., and after a careful
massage to detach all the cells in the cavity, peritoneal fluid was
collected through a 23G syringe. Tubes were weighed to de-
termine the recovered lavage volume, and the cell density was
assessed using a hemocytometer. All mice were housed at the
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animal facility at CIML with water and food provided ad libi-
tum and a 12-h night/daylight cycle. All animal experiments
were approved and performed in accordance with the limiting
principles for using animals in testing (the three R’s: replace-
ment, reduction, and refinement) and approved by the French
Ministry of Higher Education and Research.
Fate-mapping experiments
Genetic fate-mapping using Cx3Cr1CreER:R26-YFP mice was
performed as previously described (Mossadegh-Keller et al.,
2017); pregnant females were pulse-labeled at E16.5 by i.p. in-
jection of 0.1 mg/kg tamoxifen and 0.05 mg/kg progesterone.
For fate-mapping in adult tumor-bearing mice, Cx3Cr1CreER:R26-
tdRFP mice were injected with 106 ID8-Luc cells i.p. and after 6
wk pulse-labeled with a single dose of 2 mg tamoxifen dissolved
in 200 µl of corn oil by oral gavage. Generation of shielded
chimeras was performed as previously described (Goossens
et al., 2019); CD45.1 congenic mice were anesthetized with ket-
amine (150 mg/kg) and xylazine (10 mg/kg) and placed in 6-
mm-thick lead cylinders, exposing only the hind legs. With the
abdominal area protected, mice were irradiated with 9 Gy and
reconstituted with 107 bone marrow cells from CD45.1/.2 mice.
After 5 wk, chimerism of blood leukocytes was assessed by flow
cytometry.
Flow cytometry and cell sorting
Single-cell suspensions were prepared from omentum by di-
gesting the tissue in RPMI 1640 medium with 1 mg/ml colla-
genase II (Sigma Aldrich), 50 µg/ml DNaseI (Roche), and 0.1%
(wt/vol) BSA for 30 min at 37°C with gentle agitation. Cell sus-
pensions were subsequently passed through a 70-µm cell
strainer (BD Biosciences) and collected by centrifugation. Blood
and ascitic cells harvested by peritoneal lavage were used
without further processing. For RBC lysis, cell suspensions were
incubated with 0.85% NH4Cl for 2 min at room temperature,
collected by centrifugation, and resuspended directly in FACS
buffer (1×PBS pH 7.4, 1 mM EDTA pH 8.0, 3% FCS, and 0.1%
NaN3). For flow cytometry, single-cell suspensions were incu-
bated at 4°C for 10 min with 2.4G2 antibody for Fc receptor
blocking followed by incubation with the specified antibodies
(see Table 1 for details) for 30 min at 4°C. Prior to analysis, cells
were incubated with Sytox Blue (Thermo Fisher Scientific) to
discriminate dead cells and filtered through a 70-µm cell
strainer. ALDH activity in tumor cells was measured using the
Aldefluor kit (Stem Cell Technologies), in accordance with the
manufacturer’s instructions. In brief, 2 × 106 cells were incu-
bated with 5 µl of Aldefluor stock solution or 5 µl of Aldefluor
stock solution in combination with 5 µl of the ALDH inhibitor
diethylaminobenzaldehyde and incubated for 30 min at 37°C.
ALDH activity was subsequently measured by flow cytometry
relative to DEAB-treated control cells. All flow cytometry
analysis was performed with either BD FACS LSR-2 or Fortessa
X-20 flow cytometers, whereas cell sorting was performed with
BD FACS Aria SORP. All cytometers were equipped with a 350-
nm laser (BD Biosciences). Subsequent data analysis was per-
formed using FlowJo software V10.4 for Mac (Tree Star).
Liposome preparation
Long-circulating liposomes encapsulating dxr were prepared
and modified for CD163 targeting as previously described (Fritze
et al., 2006; Etzerodt et al., 2012). Briefly, liposome formulations
were formed using the ethanol-injection method from a mixture
of hydrogenated soy L-α-phosphatidylcholine, mPEG2000-PE,
and cholesterol (molar ratio of 55:40:5; Lipoid GmBH and Sigma
Aldrich). Lipids were dissolved in ethanol at 65°C for 15 min
followed by hydration (to 10% EtOH) for 1 h at 65°C in aqueous
Table 1. Antibodies used for flow cytometry analysis
Antigen Clone Dye Catalog number Supplier
CD45.2 104 BUV737 564880 BD Biosciences
MHCII M5/114.15.2 A700 56-5321-82 eBioscience
CD11b M1/70 BV395 563553 BD Biosciences
F4/80 BM8 BV785 123141 Biolegend
CD163 R34 CF405
CD64 X54-5/7.1 BV711 139311 Biolegend
CD169 SER-4 eFluor660 50-5755-82 Invitrogen
CCR2 475301 APC FAB5538A R&D Systems
Ly6C AL-21 FITC 553104 BD Biosciences
Tim4 54(RMT4-54) PerCP-Cy5.5 46-5866-82 eBioscience
Siglec F ES22-10D8 PE 130-102-274 Miltenyi Biotec
CD5 53-7.3 BV605 563194 BD Biosciences
CD19 1D3 BUV661 565076 BD Biosciences
Lyve1 ALY7 A488 53-0443-82 eBioscience
NK1.1 PK136 APC-Cy7 108724 Biolegend
Ly6G 1A8 APC-Cy7 560600 BD Biosciences
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buffer suitable for further downstream applications. Liposomes
were sized by extrusion 25 times through a 0.1-µm filter using
the Avanti mini-extruder kit (Avanti Polar Lipids) and dialyzed
twice against 150 mM NaCl (0.9% NaCl) with a second dialysis
being done overnight at 4°C. For remote loading of dxr, lipid was
hydrated in 300 mM (NH4)2HPO3. Following extrusion and di-
alysis, (NH4)2HPO3-containing liposomes were mixed with dxr-
HCl for 30 min at 65°C at a dxr:lipid ratio of 1:5. Lipid content,
drug content, and encapsulation efficiency were subsequently
estimated from high-pressure size-exclusion chromatography
(UV absorbance at 210 nm) using a Dionex Ultimate 3000 HPLC
system (Thermo Fisher Scientific) equipped with an Ascentis
C18 column (Sigma Aldrich). Liposome size was estimated using
dynamic light scattering and the DynaPro NanoStar system
(Wyatt Technology Europe GmbH). Modification of liposomes
for CD163 targeting was done as described previously using the
post-insertion method of the αCD163 antibody, clone 3E10B10
(Etzerodt et al., 2012; Torchilin et al., 2001).
Immunohistochemistry and whole-mount
immunofluorescence imaging
Omentum was fixed in 1% formalin and either embedded in
optimal cutting temperature compound for cryostat sectioning
or used directly for whole-mount imaging. For histological
analysis, 10-µm cryostat sections were mounted on glass slides
and stained with H&E and visualized on an upright microscope
equipped with a 10× objective. For whole-mount imaging,
omental tissue was incubated with anti-CD163-ATTO565
(Etzerodt et al., 2013), anti-CD169-eFluor660 (Clone Ser4;
eBioscience), anti-CD45.2-Alexa488 (Clone 104; Biolegend), and
Tim4-Alexa647 (RMT54-4; Biolegend) in 0.1 M Tris pH 7.2, 1%
Triton X-100, 0.5% BSA overnight at 4°C. Nuclei were visualized
with Hoechst 33342 (Sigma Aldrich). Tissue was subsequently
mounted in RapiClear 1.47 for tissue clearing on glass slides with
a 0.2-mm iSpacer (SunJin Lab Co.). Images were acquired on a
Zeiss LSM780 confocal microscope (Carl Zeiss Microscopy
GmbH) using spectral unmixing with a 10× or 20× objective.
Spheroid formation assay
Tumor cells in ascites were enriched by depleting leukocytes in
peritoneal lavage using the CD45.2 magnisort kit (eBioscience)
and seeded at 40,000 cells per well in ultra-low-attachment 96-
well plates (Corning Life Science) in DMEM supplemented with
4% heat-inactivated FCS. Formation of spheroids was subse-
quently monitored by microscopy using an inverted microscope
equipped with a 4× objective.
scRNA-seq
Single-cell tumor suspensions were prepared from mouse
omentum infiltrated with epithelial cancer cells 10 wk after
inoculation. Macrophages were isolated by flow-assisted cell-
sorting gating on CD11b+, Linneg, F4/80+, and CD64+. Single-cell
transcriptomes were generated from roughly 4,000 cells per
mouse (n = 4; total of 16,510 cells after CellRanger filtering) using
ChromiumNext GEM Single Cell 39 GEMkit v2 and sequenced to
a depth of, on average, 45,000 reads per cell using a NovaSeq
S2 flow cell. This averaged to ∼1,400 genes per cell. After
sequencing, samples were processed with 10× Genomics Cell-
Ranger pipeline (version 2.1.0) using mm10 (v2.1.0) reference
genome. Filtered read count matrices were analyzed with Seurat
(v3.1.0) running in R (v3.6.1). Briefly, samples were normalized
with SCTransform (Hafemeister and Satija, 2019; 13,886 genes
retained) and subsequently filtered to remove cells with high
mitochondrial read contamination (>15%), low gene detection
rate indicative of low-quality cells (<200), and high gene de-
tection rate (>4,000) or high read count (>20,000) indicative of
doublets. After filtering, 16,392 cells remained. Subsequently,
cells were clustered into 10 clusters using Louvain clustering
(resolution = 0.5), and UMAP was used to visualize clusters
(assay = “SCT,” reduction = “pca,” dims = 1:10). Cluster marks
were identified by comparing each cluster to all other clusters
using the default Wilcoxon Rank Sum test and the default logFC
threshold (>0.25). Only genes expressed in ≥25% of cells in
either the cluster or all other clusters combined were consid-
ered, and only genes up-regulated in the cluster compared with
all other clusters combined were reported. The top 10 cluster
markers were selected by first sorting by lowest P value and
subsequently by highest fold-change. Datasets are available at
the European Bioinformatics Institute under accession no.
E-MTAB-8593.
Bulk RNAseq and bioinformatics analysis
Library preparation and RNAseq was performed by the Ge-
nomEast platform at Institut de Génétique et Biologie Molécu-
laire et Cellulaire, Strasbourg, France. Full-length cDNA was
generated using a Clontech SMART-Seq v4 Ultra Low Input RNA
kit (Takara Bio Europe) according to the manufacturer’s in-
structions from 500 cells isolated by cell sorting in PBS buffer
containing RNase inhibitor. cDNA was amplified with 14 cycles
of PCR for cDNA amplification by Seq-Amp polymerase. 600 pg
of preamplified cDNAwas then used as input for Tn5 transposon
tagmentation by the Nextera XT DNA Library Preparation Kit
(96 samples; Illumina) followed by 12 cycles of library amplifi-
cation. Following purification with Agencourt AMPure XP beads
(Beckman-Coulter), the size and concentration of library DNA
were assessed on an Agilent 2100 Bioanalyzer. Libraries were
sequenced on an IlluminaHiSeq4000 platform generating 50-bp
reads. Samples were trimmed to remove TruSeq adapters using
BBduk (Bushnell, 2014) and subsequently mapped to the mouse
genome assembly version mm10 using STAR version 2.5.3a
(Dobin et al., 2013) with junction annotation from Ensembl
version 79 (Yates et al., 2016). Gene counts obtained directly
from STAR were used in gene expression analysis with DESeq2
(Love et al., 2014) using cqn (Hansen et al., 2012) derived nor-
malization factors. SOM clustering analysis was performed us-
ing the “kohonen” R pacakage (Wehrens and Kruisselbrink,
2018; Wehrens and Buydens, 2007), while comparative GO
analysis was performed using clusterProfiler (Yu et al., 2012).
Heatmaps and hierarchical clustering were generated using the
One minus Pearson correlation, and PCA plots with network
analysis (using Pearson correlation) to show the three nearest
neighbors were generated using Qlucore Omics Explorer (Qlu-
core AB). Datasets are available at the European Bioinformatics
Institute under accession no. E-MTAB-8140 and E-MTAB-8141.
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Gene expression analysis
Total RNA was purified from sorted cell populations using the
RNeasy Micro Kit (Qiagen), and concentration was determined
using the Quant-IT RiboGreen RNA assay kit (Thermo Fisher
Scientific). First-strand cDNA synthesis was performed with a
High Capacity cDNA Reverse Transcription Kit (Thermo Fisher
Scientific) followed by preamplification of genes of interest us-
ing the Fluidigm PreAmp Master Mix (Fluidigm Europe B.V.)
with 25 ng of total RNA and in accordance with the manu-
facturer’s instructions. Exon-spanning primers to amplify genes
of interest were designed using Primer-Blast (see Table 2 for
details). To increase sensitivity, genes of interest were pre-
amplified by 12 cycles of PCR using pooled assays followed by
exonuclease I treatment (New England Biolabs) to remove un-
incorporated primers. Final preamplified cDNA was diluted 1:5
in Tris-EDTA buffer. Gene expression analysiswas performed using
the Biomark HD system from Fluidigm (Fluidigm Europe B.V.) in
accordance with the manufacturer’s instructions and standard
settings. Data were analyzed using the Real-Time PCR Analysis
Software (Fluidigm Europe B.V.), and the resulting cycle threshold
values were normalized to Ppia to obtain delta CT values.
Statistical analysis
For treatment studies, statistical analysis was performed using
two-way ANOVA followed by Tukey post-hoc test. For com-
parison between groups, statistical testing was performed using
nonparametric tests such as Mann-Whitney U test or Kruskal-
Wallis followed by Dunn’s multiple comparisons test. P values
are indicated as *, P < 0.05; **, P < 0.01; ***, P < 0.001; and ****, P <
0.0001. All statistical analysis was performed with Graphpad
Prism 7 for Mac.
Online supplemental material
Fig. S1 shows the gating strategy for macrophages in omentum.
Fig. S2 shows the flow cytometric analysis of monocytic chi-
merism in the shielded chimera fate-mapping experiments. Fig.
S3 shows a heatmap of the 5,000 most DEGs in CD169hi Lyve-1+
omental macrophages sorted at steady state (0 wk) or 5 wk and
10 wk after infiltration of ID8 ovarian cancer cells. Fig. S4 shows
tumor growth in Ccr2−/− mice as well as replenishment of
omental and peritoneal macrophages after prophylactic deple-
tion of CD163+ macrophages in Cd163-Csf1rDTRmice. Fig. S5 shows
heatmaps of genes associated with enriched pathways in P1–P3
omental macrophages. Fig. S5 also shows the transcriptomic
comparison of cultured ID8 cells with ID8 cells harvested from
ascites. Table S1 lists markers associated with CSC phenotype in
ovarian cancer.
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Figure S1. Gating strategy and expression of Tim4 and CD163 on omental macrophages. (A) Gating strategy for the myeloid cell compartment excluding
neutrophils. Myeloid cells were gated as Live (forward scatter area [FSC-A] versus Sytox Blue), CD45.2+ (CD45.2 versus SSC-A), CD5−, CD19− (CD5 versus
CD19), Linneg(NK1.1, Ly6G), CD11b+ (CD11b versus Lineage), single cells (forward scatter height [FSC-H] versus forward scatter width [FSC-W]), and CD64+ and
F4/80+ (F4/80 versus CD64). (B) Expression of CD163 and Tim4 among F4/80+ CD64+ macrophages that are CD169negLyve-1neg (green), CD169int Lyve-1neg
(red), or CD169hi Lyve-1pos (blue). Data are representative of two independent experiments.
Etzerodt et al. Journal of Experimental Medicine S1
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Figure S2. Fate mapping of omental macrophages. (A and B) Flow cytometric analysis of blood monocytes in mice 5 wk (A) or 13 wk (B) after adoptive
transfer of CD45.1+/CD45.2+ donor bone marrow in irradiated CD45.1+ host mice that were protected by a lead shield. Monocytes were gated as Live (FSC-A
versus Sytox Blue), CD5neg, CD19neg (CD5 versus CD19), NK1.1neg, CD11b+ (CD11b versus NK1.1), and Ly6C+, Ly6Gneg (Ly6C versus Ly6G). Data are represented
as mean ± SEM of n = 5. (C) Flow cytometric analysis of YFP+ microglia in Cx3Cr1CreER:R26-yfp mice pulse-labeled with tamoxifen at E16.5. Microglia were
gated as Live (FSC-A versus Sytox Blue), Ly6Cneg, CD11cneg (Ly6C versus CD11c), and CD45.2dim, CD11bhi (CD11b versus CD45.2). Data are represented as mean
± SEM of n = 6. All data are representative of two independent experiments.
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Figure S3. Hierarchical clustering analysis of omental macrophages. (A) Heatmap showing hierarchical clustering analysis of the 5,000 most DEGs in P1
(green), P2 (red), and P3 (blue) CD169hi Lyve-1pos omental macrophages sorted at steady state (0 wk) or 5 wk and 10 wk after infiltration of ID8 ovarian cancer
cells. (B) Heatmap showing expression of macrophage markers from transcriptomic analysis of P1 (green), P2 (red), and P3 (blue) CD169hi Lyve-1pos omental
macrophages sorted 10wk after ID8 injection (Fig. 2 E). Libraries were prepared from two independent experiments with n = 2 and sequenced on the same flow
cell for a total of four biological replicates.
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Figure S4. Depletion of monocyte-derived and tissue-resident omental macrophages. (A and B) Flow cytometric analysis of CD169hi Lyve-1pos omental
macrophages in Ccr2−/− mice 10 wk after i.p. injection of 106 ID8 ovarian cancer cells. Data are represented as mean ± SEM of n = 5, and statistically significant
difference was calculated using two-way ANOVA followed by Tukey post hoc test; *, P < 0.05; ****, P < 0.0001. (C and D) Omentum weight (C) and number of
tumor cells in ascites (D) of WT and Ccr2−/− mice 10 wk after injection of ID8 cells. Data are represented as mean ± SEM of n = 6, and statistically significant
difference was calculated using Mann-Whitney U test; *, P < 0.05. (E–G) Flow cytometric analysis of CD169hi Lyve-1pos omental macrophages in Cd163-Csf1rDTR
mice 1 d (E) or 6 d (F and G) after i.p. injection of 4 ng/kg DT. CD169hi Lyve-1pos omental macrophages were gated as described in Fig. S1 A. (H) Flow cytometric
analysis of peritoneal macrophages in Cd163-Csf1rDTR and control mice 6 d after i.p. injection of 4 ng/kg DT. Peritoneal macrophages were gated as Live,
CD45.2pos, Linneg(CD5,CD19, Ly6G, NK1.1) CD11b+, F4/80+, and MHCIIneg. Data are represented as mean ± SEM of n = 7, and statistically significant difference was
calculated using Mann-Whitney U test; *, P < 0.05. All data are representative of two independent experiments.
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Figure S5. Transcriptomic analysis of ID8 ovarian cancer cells and TAMs from omentum. (A–D) Heatmaps showing expression of genes associated with
the enriched pathways in Fig. 5 E: Positive regulation of JAK-STAT (A), angiogenesis (B), regulation of tissue remodeling (C), and T cell differentiation (D). (E) GO
term enrichment analysis of RNAseq data comparing cultured ID8 cells (n = 4) and ID8 cells harvested from ascites 11 wk after transplantation in vivo (ID8-A11,
n = 4). Identified GO terms are represented by nodes with a size according to the number of enriched genes. Nodes are colored according to the normalized
enrichment score (NES). (F) GSEA comparing ID8 and ID8-A11 against the hallmark gene sets in MSigDB. (G) Flow cytometric analysis of CSC markers CD54,
CD55, CD106, and CD117 on tumor cells from ascites of mice specifically depleted of Tim4+ CD163+ resident TAM (αCD163-dxr). Mice were injected i.p. with
1 mg/kg αCD163-dxr or controls (empty αCD163-LNP or PBS) on days 1, 3, and 5, before injection of ID8-Luc cells i.p. on day 8. 10 wk after ID8, tumor cells in
ascites were harvested and analyzed for CSC marker expression by flow cytometry by gating on Live, CD45.2neg, and Linneg(CD11b, F4/80, CD5,CD19, Ly6G, NK1.1) cells.
(H)Heatmap showing expression levels of TFs involved in EMT andMET in ID8 and ID8-A11 cells. All data are representative of three independent experiments.
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Table S1 is provided online as a separate Word file and lists markers associated with CSC phenotype in ovarian cancer.
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